Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):585–593. doi: 10.1097/QAI.0000000000002079

Table 1:

Baseline Characteristics

Switch from EFV+FTC/TDF to:
EVG/c/FTC/TDF
(n=10)
RAL+FTC/TDF
(n=10)
p-value All participants
(n=20)
No. of participants 10.0 10.0 - 20.0
Age (mean) 46.5 (9.0) 47.9 (9.9) 0.7 47.2 (9.2)
Male gender (%) 90 60 - 75
CD4 T cell (mean) 657 (187) 709 (280.5) 0.6 683 (234)
HIV-1 RNA <20 copies/ml (%) 80.0 80.0 - 80.0
On ART (%) 100 100 - 100
Creatinine (mean) 0.9 (0.2) 0.8 (0.2) 0.4 0.9 (0.2)
Cholesterol (mean) 178.8 (24.2) 200.9 (37.0) 0.1 190.0 (32.5)
% on statin 10 30 - 20
ALT (mean) 26.2 (15.2) 28.6 (15.1) 0.6 27.4 (14.8)
EFV plasma conc (mcg/ml)* 2.3 (0.9) 3.9 (2.3) 0.1 3.1 (1.9)
   8-OH EFV conc 0.6 (0.4) 0.5 (0.4) 0.8 0.5 (0.4)
   7-OH EFV conc 0 (0) 0.01 (0.01) 0.1 0.01 (0.01)
Post- EFV plasma conc (mcg/ml) 0.02 (0.05) 0 (0) 0.4 0.4 (0.7)
   Post 8-OH EFV conc 0 (0) 0 (0) 0.3 0 (0)
   Post 7-OH EFV conc 0 (0) 0.01 (0.01) 0.05 0 (0)
*

mean (stdv)